U.S. FDA advisory panel votes in favor of Johnson & Johnson’s COVID-19 vaccine
(Reuters) – A panel of expert advisers to the U.S. Food and Drug Administration (FDA) on Friday voted in favor of authorizing Johnson & Johnson’s COVID-19 vaccine for emergency use, bringing it an important step closer to a U.S. rollout.
The FDA is likely to authorize the one-shot vaccine within a day or so after receiving the recommendation of the panel, making it the third available in the United States.
Reporting by Manas Mishra in Bengaluru; editing by Peter Henderson
Our Standards: The Thomson Reuters Trust Principles.
vaccine fda coronavirus covid-19
- Top NASDAQ Gaming Stocks April 22, 2021
- Emergent BioSolutions Shares Dive After FDA’s Stinging Report on COVID-19 Vaccine Manufacturing Plant April 22, 2021
- U.S. States are Next on the List for Psychedelic Legalization April 22, 2021
- 3 Top Growth Stocks to Buy Today April 22, 2021
- Should You be Investing in Renewable Energy? April 22, 2021